Axcelead, Inc.
Axcelead is a Japanese private healthcare platform company offering integrated drug discovery services—from target identification through IND-enabling studies—to pharmaceutical companies, biotech ventures, and academic institutions, leveraging Takeda-inherited compound libraries, proprietary AI tools (Beyond-A, Druggable Target 1000), and the ATWP JV with Teijin.
- Company typePrivate
- Founded2017
- HeadquartersMinato-ku, Tokyo, Japan
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Axcelead, Inc. does
Axcelead, Inc. is a Japanese healthcare platform company that, as of the most recent disclosed data, operated two core pillars: integrated drug discovery services through Axcelead Drug Discovery Partners (ADDP) and Axcelead Tokyo West Partners (ATWP, a 51/49 JV with Teijin), and mRNA pharmaceutical CDMO through ARCALIS. In April 2026 the company completed an absorption-type company split that separated the mRNA CDMO business into ARCALIS Holdings, leaving Axcelead focused on its drug discovery solution business. ADDP was established in July 2017 through the spin-off of Takeda Pharmaceutical's drug discovery platform business and inherited Takeda's 120,000+ compound library, 200+ drug seeds, advanced HTS systems, and 30+ years of accumulated research data — making it Japan's first dedicated drug discovery solution provider. ATWP, formed in April 2024, added approximately 100 Teijin Pharma researchers to the group.
The platform offers services spanning target identification through IND-enabling studies, including the proprietary IND-Enabling Projects (A-HiT) library covering 150+ targets (~60% at lead generation or beyond, ~50% potentially First-In-Class, ~30% with co-crystal structures). Technology infrastructure includes the Beyond-A AI foundation model project (integrating proprietary datasets with wet-lab validation), Druggable Target 1000 (joint with FRONTEO using Concept Encoder over 20M+ papers), and the A-Digital IoT/cloud platform. The company reported an ~85-90% client repeat rate, ~90% of Japanese pharma R&D companies as clients, and 200+ cumulative client engagements since founding; named customers include Otsuka Pharmaceutical, Kyowa Kirin, Astellas Pharma, Eli Lilly, Acadia Pharmaceuticals, and A2 Healthcare.
Axcelead generates revenue through fee-for-service drug discovery contracts (project fees, milestone payments, multi-year contracts) and previously through mRNA CDMO manufacturing fees (now separated). Distribution is exclusively direct enterprise sales targeting pharma companies, biotech ventures, academia, and government research institutes. The company maintains active global business development including three consecutive years presenting at the J.P. Morgan Healthcare Conference. In July 2026, Mitsubishi Corporation took a strategic equity stake and signed a business partnership, while Whiz Partners (via the Drug Discovery Innovation Fund and Healthcare New Platform Fund with Takeda) remains a foundational capital partner. The company is privately held, incorporated in Japan, headquartered in Minato-ku, Tokyo, and operates research and manufacturing sites across Kanagawa, Tokyo, Chiba, and Fukushima.
Axcelead, Inc. firmographics
Firmographics- Name
- Axcelead, Inc.
- Legal name
- アクセリード株式会社 (Axcelead, Inc.)
- Website
- https://axcelead-hd.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Axcelead is a Japanese private healthcare platform company offering integrated drug discovery services—from target identification through IND-enabling studies—to pharmaceutical companies, biotech ventures, and academic institutions, leveraging Takeda-inherited compound libraries, proprietary AI tools (Beyond-A, Druggable Target 1000), and the ATWP JV with Teijin.
- Ownership category
- akta.pro rank
Axcelead, Inc. industry classification
Industry- Product category
- Pharmaceutical Drug Discovery CRO Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Small-Molecule API & Intermediates CDMO (HLAGABAA)
Keywords
Where Axcelead, Inc. is headquartered
LocationHeadquarters
- HQ city
- Minato-ku, Tokyo
- HQ country
- Japan
- HQ region
- Asia
Offices5 records
Markets served
Axcelead, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Drug Discovery Support Services: Fee-for-service model providing contracted research services to pharmaceutical companies, biotech ventures, and academic institutions. Services span from target identification through IND-enabling studies. Revenue derived from project fees, milestone payments, and service contracts.
- mRNA CDMO Manufacturing: Contract development and manufacturing services for mRNA pharmaceuticals and vaccines. ARCALIS provides GMP-compliant API and formulation manufacturing. Revenue from manufacturing fees and long-term supply agreements with pharmaceutical partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Axcelead, Inc. product offering
Product offeringCore offering
Axcelead provides integrated drug discovery support services (contract research) through its core subsidiary Axcelead Drug Discovery Partners (ADDP), spanning target identification, hit-to-lead generation, and IND-enabling studies. The company also operated ARCALIS, Asia-Pacific's first integrated mRNA pharmaceutical CDMO for contract manufacturing of mRNA APIs and formulations. Additional offerings include AI-driven target evaluation, a 150+ target IND-enabling project library, and digital drug discovery platforms.
Product overview
Axcelead operates a healthcare platform business comprising two main pillars: drug discovery solutions and mRNA CDMO services. The core drug discovery platform is anchored by Axcelead Drug Discovery Partners (ADDP), Japan's first integrated drug discovery CRO, supported by joint venture Axcelead Tokyo West Partners (ATWP) with Teijin. The mRNA CDMO business is conducted through ARCALIS. Additional offerings include digital drug discovery platform A-Digital, transdermal drug delivery technology from PassPort Technologies, AI-driven drug discovery research through the Beyond-A project, and target evaluation services via Druggable Target 1000. The company supports diverse clients including pharmaceutical companies, biotech ventures, and academia.
Differentiator
Problem solved
Functional benefit
Brands
- Axcelead Drug Discovery Partners: Japan's first drug discovery solution provider offering comprehensive drug discovery services from target identification through clinical development support
- Axcelead Tokyo West Partners
- ARCALIS
- A-Digital
Products and services
- Axcelead Drug Discovery Partners (ADDP) Drug Discovery Support Services Integrated drug discovery research services for pharmaceutical companies, biotech ventures, and academia, spanning target identification, hit-to-lead chemistry, ADME/PK studies, and IND-enabling non-clinical research. Services leverage a 120,000+ compound library, 200+ drug seeds, advanced screening systems, and 30+ years of accumulated data inherited from Takeda Pharmaceutical.
- ARCALIS mRNA CDMO Services Contract development and manufacturing organization (CDMO) services for mRNA pharmaceuticals and vaccines, providing GMP-compliant API (up to 5kg annual capacity), LNP bulk, and formulation manufacturing from a single integrated facility in Minamisoma, Fukushima. Services for both clinical and commercial supply.
- Axcelead Tokyo West Partners (ATWP) Drug Discovery Research Services Integrated drug discovery research services combining Teijin Pharma's research capabilities with Axcelead's ADDP platform. Approximately 100 researchers provide comprehensive drug discovery CRO services from target validation through lead optimization.
- Druggable Target 1000 (AI Target Evaluation Service) AI-based drug target evaluation service that analyzes 20 million+ medical papers using FRONTEO's Concept Encoder to comprehensively and objectively assess the potential of target molecules, enabling industrialization of drug discovery through integration with Axcelead's data.
- IND-Enabling Projects (A-HiT) Asset Library Pre-built drug discovery asset library providing access to hit/lead compounds and primary assay systems for over 150 targets. Approximately 60% of projects are at lead generation or beyond, with half potentially First-In-Class. About 30% of targets have co-crystal structures obtained, enabling accelerated program starts for partners.
Quantifiable outcome
- Approximately 85-90% client repeat rate
- +5 more outcomes
Companies that use Axcelead, Inc.
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
Axcelead, Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature5 records
Axcelead, Inc. partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered major, important, core and supporting.
- Mitsubishi Corporation (三菱商事株式会社)majorStrategic business partnership announced July 2026. Mitsubishi Corporation brings extensive business foundation, global network, and business development capabilities. Partnership aims to accelerate Axcelead's drug discovery business growth and create new business opportunities. Mitsubishi also acquired some Axcelead shares as part of this partnership.
- A2 Healthcare Corporation (エイツーヘルスケア株式会社)importantBusiness partnership to promote pharmaceutical R&D in Japan. Combined capabilities enable seamless support from drug discovery research, non-clinical trials, clinical trials, regulatory approval, to manufacturing. Both companies contribute to drug loss reduction and strengthening Japan's drug discovery ecosystem.
- Fukushima Medical University (福島県立医科大学)importantPartnership agreement with Fukushima Medical University and Fukushima Medical University Translational Research Organization for mRNA pharmaceutical R&D and manufacturing. Supports regional healthcare innovation and mRNA technology development in Fukushima Prefecture.
- National Cancer Center (国立研究開発法人国立がん研究センター)importantPartnership agreement for mRNA pharmaceutical R&D and manufacturing. ARCALIS supports NCC-CPOT (Translational Research Promotion Center) in social implementation of mRNA drug discovery seeds. Collaborates with NCC-EPOC (Exploratory Oncology Research Center) for clinical trial promotion as CDMO partner.
- Teijin Limited (帝人株式会社)coreJoint venture Axcelead Tokyo West Partners established April 1, 2024 (51% Axcelead, 49% Teijin). Inherits Teijin Pharma's drug discovery research functions including ~100 researchers. Provides comprehensive drug discovery CRO services with Teijin's research capabilities integrated with ADDP platform.
- Tokyo Medical and Dental University (東京医科歯科大学)importantJoint research on mRNA therapeutics for acute cerebral infarction and post-resuscitation brain injury. TMDU provides BDNF mRNA delivery technology; ARCALIS and Axcelead DDP provide mRNA manufacturing, formulation, IP, and personnel expertise. Aims for world's first radical treatment for ischemic CNS diseases.
- Arcturus Therapeutics Holdings, Inc.coreJoint venture partnership to establish ARCALIS, Japan's first integrated mRNA CDMO. Arcturus provides mRNA manufacturing technology licensing and serves as key shareholder. Facility in Minamisoma, Fukushima provides GMP-compliant API and formulation manufacturing for mRNA vaccines and therapeutics.
- Meiji Seika Pharma Co., Ltd. ( Meiji Seikaファルマ)majorMeiji Seika Pharma manufactures and markets ARCT-154 (self-amplifying mRNA COVID-19 vaccine) in Japan with ARCALIS providing API manufacturing. Partnership expanded with Meiji Seika taking equity stake in ARCALIS (November 2024). ARCALIS's Minamisoma facility produces API for domestic supply.
- FRONTEO Inc. (株式会社FRONTEO)importantAI-powered drug target evaluation partnership 'Druggable Target 1000'. FRONTEO's Concept Encoder AI analyzes medical literature for comprehensive, objective evaluation of target molecule potential. Integrated with Axcelead's data for 'industrialization of drug discovery'.
- Hitachi, Ltd. (株式会社日立製作所)importantJoint development of next-generation biopharmaceutical solutions. Provides cell manufacturing process development services combining Hitachi's automated cell culture systems with Axcelead DDP's cell/gene therapy expertise. Also provides IoT/cloud-based CHIPS service for manufacturing visibility.
- IP Generator Co., Ltd. (IPジェネレーター株式会社)importantThree-party comprehensive business partnership with IPG and ADDP to build drug discovery platform from research seeds to market. IPG selects promising research seeds, Axcelead provides Druggable Target 1000 database access, and ADDP conducts non-clinical R&D. IPG provides IP rights to pharma companies at lower prices with success fee sharing.
- NVIDIA CorporationsupportingMember of NVIDIA Inception Program, an AI startup support program. Axcelead gains access to NVIDIA's cutting-edge GPU technology and deep learning expertise to enhance drug discovery AI platform, predictive analysis, and molecular modeling capabilities.
Scale indicators9 records
Recent moves10 records
Expansion highlights6 records
Axcelead, Inc. competitors and assessment
Company assessmentDirect peers
- Evotec: European drug discovery CRO with AI/data-driven platform - directly comparable integrated discovery CRO serving pharma clients with multi-modality capabilities (small molecules through biologics).
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining wet-lab validation with proprietary datasets - directly comparable to Axcelead's Beyond-A model using AI foundation models integrated with CRO operations.
- WuXi AppTec: China-based integrated CRO/CDMO offering discovery, development, and manufacturing services comparable to Axcelead's full-spectrum drug discovery platform, serving global pharma companies with similar modalities.
- CMIC Holdings: Japan's largest CRO providing drug development services to Japanese pharma - directly competes in the same domestic market with overlapping customer base of Japanese pharmaceutical companies.
Regional players
- EPS Holdings: Japan-focused CRO/CDMO with drug discovery and clinical development services - comparable regional competitor serving Japanese pharma clients with similar service portfolio breadth.
- Inabata & Co: Japan-based life sciences and chemicals distributor with healthcare-related business - serves as a regional Japanese comparator in the broader pharma services ecosystem.
Emerging players
- Schrödinger: AI-driven computational drug discovery platform with pharma partnerships - overlaps with Axcelead's Druggable Target 1000 / Beyond-A AI initiatives but lacks integrated wet-lab CRO services.
Broad incumbents
- Syneos Health: Global CRO offering clinical and commercial services to biopharma - competes for outsourced pharma R&D budgets though more focused on later-stage clinical work than early discovery.
- IQVIA: World's largest CRO with integrated clinical and commercial services including R&D solutions. Competes with Axcelead on outsourced pharma research services, particularly for global pharma clients.
- Charles River Laboratories: Global CRO offering discovery services, safety assessment, and manufacturing support - directly competes with ADDP in early-stage drug discovery services for pharma clients, with a much larger global footprint.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Axcelead, Inc. social profiles
Digital presenceAxcelead, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Axcelead, Inc. leadership team
Management profileNumber of profiles
Profiles10 records
Axcelead, Inc. subsidiaries and ownership
Company hierarchySubsidiaries5 records
Axcelead, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Axcelead, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Axcelead, Inc.
What does Axcelead, Inc. do?
Axcelead provides integrated drug discovery support services (contract research) through its core subsidiary Axcelead Drug Discovery Partners (ADDP), spanning target identification, hit-to-lead generation, and IND-enabling studies. The company also operated ARCALIS, Asia-Pacific's first integrated mRNA pharmaceutical CDMO for contract manufacturing of mRNA APIs and formulations. Additional offerings include AI-driven target evaluation, a 150+ target IND-enabling project library, and digital drug discovery platforms.
Is Axcelead, Inc. a public or private company?
Axcelead, Inc. is a private company. It is classified as venture growth investor backed and is currently operating.
When was Axcelead, Inc. founded?
Axcelead, Inc. was founded in 2017. It employs 11 to 50 people.
Where is Axcelead, Inc. based?
Axcelead, Inc. is headquartered in Minato-ku, Tokyo, Japan, in the Asia region.
How does Axcelead, Inc. make money?
Two revenue lines are on record. Drug Discovery Support Services are the primary driver. The others are mRNA CDMO Manufacturing.
Who are Axcelead, Inc.'s main competitors?
Direct peers on record are Evotec, Recursion Pharmaceuticals, WuXi AppTec and CMIC Holdings. Regional players are EPS Holdings and Inabata & Co. Schrödinger is listed as an emerging player. Broad incumbents are Syneos Health, IQVIA and Charles River Laboratories.
Does Axcelead, Inc. have an API?
No public API is recorded for Axcelead, Inc..
What industry is Axcelead, Inc. in?
Axcelead, Inc.'s product category is Pharmaceutical Drug Discovery CRO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO. Its NAICS code is 541714 and its SIC code is 8731.